


**IRON-FREE TRANSFERRIN  
APOTRANSFERRIN AS A NEW  
TREATMENT TO IMPROVE STROKE  
OUTCOME IN INTRACEREBRAL  
HEMORRHAGE**

**Teresa Gasull**, CMN research group  
Germans Trias i Pujol Research Institute  
Barcelona, October 8th 2024  
tgasull@igtp.cat

# Background



Primary brain injury

- Mass effect
- Intracranial pressure
- Herniation
- Blood flow
- Tissue disruption
- ...



BBB disruption

Neuronal damage

Cerebral edema





Secondary brain injury

- Erythrocyte lysis
- Hemoglobin
- ROS
- Heme group & iron
- Inflammation
- ...




# Background

Immunohistochemistry  
(Multiple Image Alignment)



DeGregorio-Rocasolano N, et al Redox Biol. 2018  
Millan M, et al. Antioxidants 2021



DeGregorio-Rocasolano N, et al Front Neurosci.. 2019



# Background: ICH & IS share ferroptosis/iron-related mechanisms

Clinical Trial > Stroke. 2022 Apr;53(4):1149-1156. doi: 10.1161/STROKEAHA.121.035421.

Epub 2021 Nov 18.

## Effect of Deferoxamine on Outcome According to Baseline Hematoma Volume: A Post Hoc Analysis of the i-DEF Trial

Chenchen Wei<sup>1,2,3</sup>, Jeffrey Wang<sup>1</sup>, Lydia D Foster<sup>4</sup>, Sharon D Yeatts<sup>4</sup>, Claudia Moy<sup>5</sup>, J Mocco<sup>6</sup>, Magdy Selim<sup>1</sup>; i-DEF Investigators

Clinical Trial > Stroke. 2022 Jul;53(7):2204-2210. doi: 10.1161/STROKEAHA.121.037298.

Epub 2022 Mar 21.


## Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial

Lydia Foster<sup>1</sup>, Laura Robinson<sup>2</sup>, Sharon D Yeatts<sup>1</sup>, Robin A Conwit<sup>3</sup>, Amjad Shehadah<sup>2</sup>, Vasileios Lioutas<sup>2</sup>, Magdy Selim<sup>2</sup>; i-DEF Investigators

> Antioxidants (Basel). 2021 Aug 10;10(8):1270. doi: 10.3390/antiox10081270.


## Targeting Pro-Oxidant Iron with Deferoxamine as a Treatment for Ischemic Stroke: Safety and Optimal Dose Selection in a Randomized Clinical Trial

Mònica Millán<sup>1</sup>, Núria DeGregorio-Rocasolano<sup>1,2</sup>, Natàlia Pérez de la Ossa<sup>1</sup>, Sílvia Reverté<sup>1</sup>, Joan Costa<sup>3</sup>, Pilar Giner<sup>4</sup>, Yolanda Silva<sup>5</sup>, Tomás Sobrino<sup>6</sup>, Manuel Rodríguez-Yáñez<sup>7</sup>, Florentino Nombela<sup>8</sup>, Francisco Campos<sup>6</sup>, Joaquín Serena<sup>5</sup>, José Vivancos<sup>8</sup>, Octavi Martí-Sistac<sup>2,9</sup>, Jordi Cortés<sup>10</sup>, Antoni Dávalos<sup>1</sup>, Teresa Gasull<sup>1,2</sup>



Zhaohui Chai, Jiesheng Zheng & Jian Shen. CNS Neurosci Ther. 2024


# Hypothesis



Apotransferrin is able to improve stroke outcome in intracerebral hemorrhage



# Results








0.5h


1.5h

5h

24h







Time after collagenase injection










# Results



# Results






## Protein







# Results





**PCBP2 = Antiferroptotic and proapoptotic effect**

## APOPTOSIS RELATED-PROTEIN



**Caspase 2 = upstream caspase effector**




# Conclusions

- 1) Apotransferrin administered intravenously during the ICH bleeding period does not reduce hematoma size or have any effect on clotting.
- 2) Apotransferrin immediately reduces TSAT in blood.
- 3) It reduces the ferroptotic marker TfR in brain tissue, with TfR1 being the main gate of iron entry in the neurons.
- 4) It normalizes the activity of PCBP2 and the activation of caspase 2.
- 5) Apotransferrin improves the sensorimotor performance of the ATf-treated mice, which is associated with a reduction of the free radicals in the areas near the hematoma.



# Thank you .RIGORS-ICTUS



## Cellular and Molecular Neurobiology group (CMN)

Teresa Gasull  
Octavi Martí-Sistac  
Núria DeGregorio-Rocasolano  
Alexia García-Serran  
Diego Sahuquillo

Jesús Ordoño  
Marina Mas-Argemí

## Neurovascular Research Group

Antoni Dávalos  
Carlos Castaño  
Maria Rosa García-Sort  
María Hernández-Pérez  
Adrián Valls-Carbó

## Proteomics and Metabolomics platform

José María Hernández

## Comparative Medicine and Bioimage Center of Catalonia (CMCiB)

Jordi Grífols  
Osvaldo Pino  
Gemma Monté-Rubio  
Josep Puig  
Marta Margalef  
Osmany Hernández  
Juan Ricardo González  
Montse Ochando  
Vanessa Figueredo



## Canon Medical Systems

Alba Iruela  
Alicia Palomar



## Universitätsklinikum Hamburg-Eppendorf (UKE)

Eva Tolosa



## University of Maryland, Baltimore,

Prof. Piotr Walczak lab



## Biomedical Research Institute of Lleida Fundació Dr. Pifarré (IRBLleida)

Francisco Purroy  
Glòria Arqué  
Cristina Pereira



## University of Georgia, Athens, US

Prof. Franklin West lab



## University of Bologna,

Maria Laura Bacci's Lab



